Welcome
Welcome to The Informer, the monthly essential newsletter for ODS-Cs and aspiring Cancer Registry professionals. Packed with specially curated educational opportunities, industry updates, and practical resources, our goal is to keep you informed and equipped to excel in this vital field. Don’t miss an edition-scroll to the bottom of this page to sign up to receive The Informer directly to your inbox.
Cancer Surveillance Community Announcements
RDU NAACCR Talk: Cancer Outcomes in Vulnerable Populations
Join the next RDU NAACCR Talk: Cancer Outcomes in Vulnerable Populations on November 16th at 2 pm eastern.
To register, click here and log in with your myNAACCR account information.
The session will feature three perspectives on using cancer registry data to evaluate differences in cancer burden and risk among different socioeconomic communities:
Cancer Outcomes in Appalachian Kentucky: Challenges, Disparities, and Opportunities
Dr. Bin Huang, Kentucky Cancer Registry
Using Registry Data to Analyze Changes in Stage-specific Female Breast Cancer Incidence by Neighborhood Gentrification status in New York City
Dr. Daniel Wiese, American Cancer Society
Cancer Prevention Potential in Atlantic Canada: Informing Local Actions on Lifestyle, Equity and Risk
Dr. Nathalie Saint-Jaques, Nova Scotia Health Cancer Program
QA knowledge challenge
Abstracting #1
Patient received SBRT for an acoustic neuroma. What Volume code will be assigned for this primary site?
A. 13 – Brain, limited
B. 98 – Other
C. 29 – Head & neck
D. 12 – Brain, whole
Abstracting #2
Patient was diagnosed with high-grade serous ovarian cancer 3/15/2026 after a biopsy of a peritoneal nodule. The treatment plan was for 6 cycles of neoadjuvant chemotherapy followed by cytoreductive surgery. Chemotherapy was completed, and repeat imaging showed a partial response to treatment. Cytoreductive surgery was done on 10/4/2026. Op report documented there was visible disease along the mesentery at the end of the procedure that was ablated with Argon beam. What will be assigned for SSDI Residual Tumor Volume Post Cytoreduction?
A. 00
B. 70
C. 80
D. 99
Your next step in cancer registry
Savista is committed to supporting your growth in the Cancer Registry field. Whether you’re looking to expand your skills or take the next step in your career, we’re here to help. Explore our open registry positions and join a team dedicated to advancing cancer data excellence.
QA knowledge challenge answer Abstracting #1
B. 98 – Other.
An acoustic neuroma is a tumor of the nerve that leads from the ear to the brain, not located within the brain itself. There is no specific volume code assigned for this primary site, so code 98 – Other is appropriate. This was confirmed with Dr. Ted Williamson, co-author of the CTR Guide to Coding Radiation Therapy Treatment.
QA knowledge challenge answer Abstracting #2
B. 70
At the completion of cytoreductive surgery, there was visible (macroscopic) disease remaining. No size was noted. The treatment of the residual disease with the Argon beam is not considered part of the cytoreductive portion of the procedure.
Join our mailing list to receive future editions to your inbox!
